NAD(+) supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling. Jiang Y, Luo Z, Gong Y, Fu Y, et al. Oncogene 2023 Jan 23. doi: 10.1038/s41388-023-02592.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jiang Y, Luo Z, Gong Y, Fu Y, et al. NAD(+) supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling. Oncogene 2023 Jan 23. doi: 10.1038/s41388-023-02592.
PMID: 36690678